Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | NAMPT | P43490 | 7/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.49 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6280117 | 0.85 | MEN1 (0.60) | TSHRCYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL6282613 | 0.83 | MEN1 (0.52) | TSHRMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12010884 | 0.81 | NAMPT (0.72) | TSHRCYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL6286589 | 0.79 | F2 (0.53) | TSHRCYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL2762052 | 0.79 | TSHR (0.53) | TSHRCYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL12010893 | 0.78 | LMNA (0.74) | TSHRCYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL2762185 | 0.78 | SMN1; SMN2 (0.49) | TSHRCYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL23059729 | 0.78 | NAMPT (0.63) | TSHRCYP2D6CYP2C9CYP2C19MAPT | |
| SCHEMBL6276930 | 0.78 | CA2 (0.53) | TSHRMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2761936 | 0.77 | CA2 (0.51) | TSHRMAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949567-B2 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2005-09-27 | — | — | US | disclosed |
| EP-1395548-A1 | DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS | 4SC AG (DE) | 2004-03-10 | — | — | EP | disclosed |
| US-20030119876-A1 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2003-06-26 | — | — | US | disclosed |
| US-20020165236-A1 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2002-11-07 | — | — | US | disclosed |
| WO-2002070467-A1 | DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS | 4SC AG (DE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165236-A1 | Compounds for the treatment of protozoal diseases | PKD2, PPOX, PKD1 | TSHR 2341/4885CYP2D6 820/4885CYP2C9 1221/4885 |
| US-20030119876-A1 | Compounds for the treatment of protozoal diseases | CLIC1, PKD2, PKD1 | TSHR 3529/4885CYP2D6 2377/4885CYP2C9 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.